HUP0105479A2 - Béta-alanin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

Béta-alanin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0105479A2
HUP0105479A2 HU0105479A HUP0105479A HUP0105479A2 HU P0105479 A2 HUP0105479 A2 HU P0105479A2 HU 0105479 A HU0105479 A HU 0105479A HU P0105479 A HUP0105479 A HU P0105479A HU P0105479 A2 HUP0105479 A2 HU P0105479A2
Authority
HU
Hungary
Prior art keywords
betha
producing
alanine derivatives
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0105479A
Other languages
English (en)
Inventor
Simon Goodman
Günter Hölzemann
Alfred Jonczyk
Wolfgang Stähle
Original Assignee
Merck Patent Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh. filed Critical Merck Patent Gmbh.
Publication of HUP0105479A2 publication Critical patent/HUP0105479A2/hu
Publication of HUP0105479A3 publication Critical patent/HUP0105479A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A tal lm ny t rgya új (I) ltal nos képletű b-alaninsz rmazékok, aholQ1, Q2, Q3, Q4, R1, R2, R3, R4, R5, R6 és n jelentése az 1. igénypontszerinti, és fiziológiailag elfogadható sói vagy szolv tjai, amelyekintegrin inhibitorok, és haszn lhatók trombózis, szívinfarktus,koszorúér szívbetegség, arterioszklerózis, gyullad s, tumor,csontritkul s, fertőzés, érplasztika ut ni resztenózis kezelésére, ésolyan folyamatokn l, amelyeket az angiogenézis tart fenn vagyterjeszt. Ó
HU0105479A 1999-02-20 2000-02-08 Betha-alanine derivatives, process for producing them and pharmaceutical compositions containing them HUP0105479A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19907370 1999-02-20
DE19957787 1999-12-01
PCT/EP2000/000969 WO2000048996A2 (de) 1999-02-20 2000-02-08 Beta-alaninderivate

Publications (2)

Publication Number Publication Date
HUP0105479A2 true HUP0105479A2 (hu) 2002-04-29
HUP0105479A3 HUP0105479A3 (en) 2002-06-28

Family

ID=26051970

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105479A HUP0105479A3 (en) 1999-02-20 2000-02-08 Betha-alanine derivatives, process for producing them and pharmaceutical compositions containing them

Country Status (21)

Country Link
US (1) US6576637B1 (hu)
EP (1) EP1153014B1 (hu)
JP (1) JP2002537287A (hu)
KR (1) KR20010093303A (hu)
CN (1) CN1146541C (hu)
AR (1) AR022628A1 (hu)
AT (1) ATE277016T1 (hu)
AU (1) AU760246B2 (hu)
BR (1) BR0008310A (hu)
CA (1) CA2371824A1 (hu)
CZ (1) CZ20012785A3 (hu)
DE (1) DE50007899D1 (hu)
DK (1) DK1153014T3 (hu)
ES (1) ES2228472T3 (hu)
HK (1) HK1042894A1 (hu)
HU (1) HUP0105479A3 (hu)
NO (1) NO20014010L (hu)
PL (1) PL350057A1 (hu)
PT (1) PT1153014E (hu)
SK (1) SK11732001A3 (hu)
WO (1) WO2000048996A2 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041423A1 (de) * 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
DE10112771A1 (de) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
DE10118550A1 (de) * 2001-04-14 2002-10-17 Merck Patent Gmbh Liganden des Integrins alpha¶nu¶beta¶6¶
DE10127041A1 (de) * 2001-06-02 2002-12-05 Merck Patent Gmbh Integrinantagonisten
DE10139059A1 (de) * 2001-08-08 2003-02-20 Merck Patent Gmbh Thioamide
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
MXPA05008313A (es) * 2003-02-06 2005-09-20 Merck Patent Gmbh Sulfonamidas peptidicas.
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
DK1667668T3 (da) * 2003-10-01 2008-09-15 Merck Patent Gmbh Alfabeta3 og altabeta6-integrinantagonister som antifibrotiske midler
MXPA06014092A (es) 2004-06-04 2007-03-15 Scripps Research Inst Composiciones y metodos para el tratamiento de enfermedades neovasculares.
EP2217238B1 (en) 2007-11-08 2014-03-12 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2666365A1 (en) * 2012-05-22 2013-11-27 Taminco Treatment of poultry, pigs or fish for reducing the feed conversion ratio.
CN104027805B (zh) * 2014-06-18 2017-02-15 北京大学 抑制整合素α5的物质在制备预防内皮细胞激活和/或动脉粥样硬化的产品中的新用途
BR112020006901A2 (pt) 2017-11-01 2020-10-13 Arrowhead Pharmaceuticals, Inc. ligantes de integrina e usos dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL327626A1 (en) 1995-12-29 1998-12-21 Smithkline Beecham Corp Antagonists of vitronectin receptor
CA2242877A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
GB2327609A (en) * 1997-07-23 1999-02-03 Merck & Co Inc A method for eliciting an avß5 or dual avß3/avß5 antagonizing effect

Also Published As

Publication number Publication date
CZ20012785A3 (cs) 2001-11-14
CA2371824A1 (en) 2000-08-24
AU3153400A (en) 2000-09-04
AR022628A1 (es) 2002-09-04
PL350057A1 (en) 2002-11-04
AU760246B2 (en) 2003-05-08
HUP0105479A3 (en) 2002-06-28
DK1153014T3 (da) 2005-01-24
EP1153014B1 (de) 2004-09-22
EP1153014A2 (de) 2001-11-14
WO2000048996A3 (de) 2000-11-16
NO20014010L (no) 2001-10-18
ES2228472T3 (es) 2005-04-16
US6576637B1 (en) 2003-06-10
HK1042894A1 (zh) 2002-08-30
CN1340046A (zh) 2002-03-13
ATE277016T1 (de) 2004-10-15
DE50007899D1 (de) 2004-10-28
CN1146541C (zh) 2004-04-21
NO20014010D0 (no) 2001-08-17
WO2000048996A2 (de) 2000-08-24
PT1153014E (pt) 2005-02-28
KR20010093303A (ko) 2001-10-27
JP2002537287A (ja) 2002-11-05
BR0008310A (pt) 2002-01-22
SK11732001A3 (sk) 2002-04-04

Similar Documents

Publication Publication Date Title
HUP0105479A2 (hu) Béta-alanin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HK1074794A1 (en) The use of substituted cyanopyrrolidines for treating hyperlipidemia
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
NZ511927A (en) Phenylglycine derivatives
ATE411288T1 (de) Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
MXPA04003245A (es) Hidroxipropilaminas.
WO2001058893A3 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
NO20010203L (no) Diacylhydrazinderivater som integrininhibitorer
TR199901962T2 (xx) Bisiklik amino asitler.
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
SE9701304D0 (sv) Compounds
MXPA03005431A (es) Derivados de urea y uretano como inhibidores de integrina.
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
BR0308195A (pt) Derivados de isoquinolina
BR0012391A (pt) Derivados de diacilidrazina
HUP0202710A2 (hu) Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE359995T1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
HUP0102370A2 (hu) Mumbaisztatin, eljárás előállítására és alkalmazása gyógyszerhatóanyagként
MX9604019A (es) Derivados de biotina.
GR3034439T3 (en) 17beta-(2-oxo-tetrahydrofuran-4-yl)-thio-androstane derivatives (17beta-(gamma-butyric acid lactone)-thio derivatives) for the treatment of inflammation and pharmaceutical compositions and a process for the production thereof
BR0113373A (pt) Derivados bifenila e o uso dos mesmos como inibidores de integrina
NO20014045L (no) Fremgangsmåte for fremstilling av derivater av bifenyl-2- karboksylsyre
HUP9904011A2 (hu) Dipeptidszármazék új sói és alkalmazásuk gyógyszerkészítmények előállítására